CM-101 in PSC Patients -The SPRING Study

Status Active, not recruiting

Clinical Trial Summary

This study is designed to assess the safety, tolerability and activity of the anti-human CCL24 monoclonal antibody CM-101 in adult subjects with Primary Sclerosing Cholangitis (PSC). At least 68 subjects at approximately 50 sites will be randomized to receive either CM-101 at doses of 10 mg/kg or 20 mg/kg or matching placebo.

Clinical Trial Description

This study will consist of a screening period, double-blind (DB) treatment period, open-label (OL) treatment period, and safety follow-up period. During the DB treatment period, subjects will receive 5 total dose administrations of study drug (investigational product - IP or placebo) once every 3 weeks (Q3W) for a coverage of 15 weeks. After completing the DB treatment period, subjects may elect to enroll in an OL treatment period. In the OL treatment period, subjects will receive a dose of IP Q3W for 11 administrations for a coverage of 33 weeks, resulting in a combined total coverage of up to 48 weeks. Subjects who do not elect to continue treatment in the OL dosing period will undergo an End of Treatment (EOT)-DB visit at Week 15 (Day 105), a Safety Follow-up Call at Week 21 (Day 147), and an End of Study (EOS) visit at Week 27. Eligible subjects who continue treatment in the OL treatment period will receive CM-101 at either a 10 mg/kg or 20 mg/kg dose commencing at Week 15 (OL Treatment 1), and the subjects will undergo an EOT-OL visit at Week 48 (Day 336), a Safety Follow-up Call at Week 54 (Day 378), and an EOS visit at Week 60 (Day 420). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04595825
Study type	Interventional
Source	ChemomAb Ltd.
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	October 1, 2020
Completion date	September 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02239211` - A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis	Phase 2
Withdrawn	`NCT03216876` - A Study Of Ursolic Acid For Primary Sclerosing Cholangitis	Phase 1
Recruiting	`NCT02605213` - Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients	Phase 4
Recruiting	`NCT01688024` - Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis	Phase 2
Completed	`NCT03041662` - Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
Completed	`NCT05866809` - Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis	Phase 2
Recruiting	`NCT05618145` - National Database on Primary Sclerosing Cholangitis (PSC)
Active, not recruiting	`NCT02446665` - Disease Status in Primary Sclerosing Cholangitis by Elastography	N/A
Completed	`NCT02247934` - Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)	N/A
Terminated	`NCT01142323` - Pilot Study of Fenofibrate for PSC	Phase 1/Phase 2
Completed	`NCT01088607` - Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis	Phase 1
Terminated	`NCT04060147` - Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis	Phase 1
Recruiting	`NCT04133792` - Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)	Phase 3
Recruiting	`NCT03183570` - Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT	Early Phase 1
Completed	`NCT02943460` - Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis	Phase 2
Completed	`NCT00951327` - Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP)	N/A
Completed	`NCT04024813` - A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC	Phase 2
Recruiting	`NCT05912387` - Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study	Early Phase 1
Completed	`NCT02884557` - NKT Role in the Regulation of the Inflammatory Bowel Disease	N/A
Recruiting	`NCT01398917` - Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis	Phase 3